Hospital Introduction

The Reproductive Medicine Center of Peking University Third Hospital is the birthplace of the first test-tube baby in the mainland of China. It integrates medicine, teaching and research. It is the world's large-scale diagnosis and treatment and comprehensive technology reproductive health research center. It has carried out a lot of systematic work around the clinical diagnosis and treatment of reproductive endocrine and infertility diseases and its clinical application basic research. In the past three years, the number of outpatient visits was 1,796,368 and 52,472 fresh IVF cycles were completed. It is one of the first batch of clinical training bases for reproductive medicine in China. It has successively produced the first and second IVF in mainland China, the first IVF in vitro, the first IVF in vitro, the world's second case and the first "three-frozen" in China. Test tube babies, etc.

With the strong support of the hospital and the orderly inheritance and construction from Professor Zhang Lizhu, the mother of IVF in China, to Academician Qiao Jie of China Academy of Engineering, the Reproductive Medicine Center has formed a research team with academicians of China Academy of Engineering, Distinguished Professor of Changjiang Scholars, winners of the National Science Fund for Distinguished Young Scholars and Outstanding Youth Fund, as well as leaders of 973, 863, the National Science and Technology Support Plan, and the National Key R & D Plan, etc. as the main academic backbones, with a stable structure and strong innovation capabilities.

The team gives full play to its collaborative innovation capabilities, integrates high-quality resources and technical strength, breaks down disciplines and field barriers, and carries out internationally leading and deeply integrated clinical, basic and transformation research around the frontier areas of reproductive health, major social and clinical needs, and common technical issues in disease diagnosis and treatment. Research, in carrying out high-quality clinical diagnosis and treatment and etiology research on reproductive health-related diseases, building a fertility testing and safety assessment system, and developing new strategies for the prevention of birth defects and genetic diseases. He has taken the lead in formulating industry norms, diagnosis and treatment guidelines, etc. in this field many times, and has a high degree of discipline planning and leadership capabilities. Carry out applied research on the improvement of clinical treatment methods, and carry out all internationally advanced assisted reproductive technologies such as routine in vitro fertilization, single sperm intra-oocyte injection, pre-implantation genetic diagnosis of embryos, assisted incubation, in vitro maturation culture of oocytes, blastocyst culture, and egg freezing.

At the same time, a series of important progress has been made in reproductive disorders, pregnancy-related diseases, fetogenic diseases, fertility protection and preservation, safety of assisted reproductive technologies, and research and development of new technologies, providing high-quality evidence-based medical evidence to improve the diagnosis and treatment of female reproductive disorders. Treating patients with severe ovarian hyperstimulation syndrome, combined with thromboembolism, and multiple pregnancy reduction surgery referred across the country. More than half of the patients with specialized and difficult diseases and patients with difficult diseases from other provinces are admitted. It has domestically leading and internationally advanced reproductive health. The level of diagnosis and treatment of difficult and critical diseases.

While developing assisted reproductive technology treatment, we are actively exploring the application of minimally invasive surgery in the diagnosis and treatment of infertility, using hysteroscopy and laparoscopy to treat endometriosis, fallopian tube diseases, uterine cavity diseases, polycystic ovary syndrome, etc.; and in response to chemotherapy and chemotherapy for malignant tumors and other issues that affect fertility, in the past three years, 28,744 cases of fertility related minimally invasive surgeries have been completed. Among them, the experience in difficult surgeries for multi-site pregnancies and rare site pregnancies is original and promoted. Multidisciplinary cooperation in reproductive medicine, obstetrics and genetics has carried out the construction of a comprehensive reproductive disease prevention and control network from communities to hospitals in 10 provinces and cities across the country for diseases affecting women's reproductive health, and established a national case database for common female reproductive endocrine diseases in communities., a national demonstration base for monitoring and demonstration of reproductive health status of women of childbearing age, a human germ cell and embryo development database, a biological sample bank and information resource platform, research on the transformation of new diagnosis and treatment technologies, Clinical medicine platforms such as clinical evaluation platform and evidence-based medicine research platform.

As the leader unit of the National Assisted Reproductive Technology Quality Management Expert Group and the Beijing City Human Assisted Reproductive Technology Quality Control and Improvement Center, we have established and improved the quality control system for assisted reproductive technology, evaluated the safety of assisted reproductive technology, and achieved pre-implantation and prenatal diagnosis of genetic diseases, breakthroughs in fetal medical treatment technology, and comprehensive treatment of early diagnosis of malignant tumors and preservation of fertility function. Assist in organizing and implementing the review and verification of assisted reproductive technologies in Beijing City. During the epidemic, national experts were organized to discuss and formulate prevention and control strategies in the implementation of assisted reproductive technologies. Develop non-invasive, accurate and efficient pre-pregnancy/pre-implantation/prenatal screening, diagnostic technologies and new technologies for early post-natal diagnosis intervention. Cross-disciplinary cooperation reveals the regulatory mechanisms of cell differentiation and organ formation during human embryonic development. MARSALA, a new method for pre-implantation genetic diagnosis of embryos, has completed the triple diagnosis of "single gene testing, chromosome identification and linkage analysis", and has given birth to the world's first MALBAC infant, improving diagnostic accuracy and reducing costs. It has been promoted to more than 50 centers, and has carried out embryonic genetic diagnosis for more than 200 monogenic genetic diseases. The level of prevention and control of birth defects ranks internationally. We have always adhered to the characteristics of mutual transformation between clinical and scientific research. Based on the National Clinical Medical Research Center for Obstetrics and Gynecology, the Key Laboratory of the Ministry of Education, the Beijing City Key Laboratory of Reproductive Endocrinology and Assisted Reproductive Technology, and the Beijing City International Cooperation Base for Prevention and Control of Birth Defects, we have built an innovative research platform integrating strategic planning, basic research, clinical research, clinical transformation, difficult diagnosis and treatment, talent training, and popularization. It has laid a good foundation for scientific and technological research and transformation of achievements in obstetric diseases.

He has won many honors including 3 second prizes in the National Science and Technology Progress Award, 2 first prizes in science and technology progress in universities of the Ministry of Education, 1 first prize in Beijing City Science and Technology Progress Award, and 1 first prize in the Chinese Medical Science and Technology Award; The research results were published in high-end journals in clinical and basic research fields such as the New England Journal of Medicine, Lancet, Nature, Science, Cell, etc., and were twice selected into the "Top Ten Advances in Science in China". The comprehensive strength, influence and reputation of the discipline have been continuously improved. It has ranked first in the "China Hospital Science and Technology Value (STEM) Ranking" released by China Academy of Medical Sciences from 2016 to 2021; in 2021, it will be ranked first in the "China Hospital Five-Year Total Science and Technology Value (ASTEM) Obstetrics and Gynecology" ranking. It is the National Clinical Research Center for Obstetrics and Gynecology (Reproductive Health), the Innovation Team of the Ministry of Education, and the Outstanding Innovative Research Group of the National Natural Science Foundation of China. In 2018, the series of research results on assisted reproductive technology of the Third Hospital of Beijing Medical University were selected as the exclusive representative of clinical technology to change people's livelihood and were selected as the "Great Change-Large-scale Exhibition Celebrating the 40th Anniversary of Reform and Opening up."

While providing high-quality medical services to patients with a high sense of responsibility and superb medical skills, the team aims at serving and promoting harmonious development of society, attaches great importance to and actively fulfills corresponding social responsibilities, and was awarded the "National Science Popularization Education Base". Assisting border areas such as Xizang, Xinjiang, Guangxi, and Ganzhou, helping cultivate grassroots medical staff, organizing grassroots free clinics, and health education and other activities. At the same time, it attaches great importance to the quality building of the department team and has won the title of "National Women's Civilization Post" and many honors such as "Beijing City March 8th Red Flag Collective".

Women's and children's health is an important cornerstone of national health. Both the "13th Five-Year Plan" for national economic and social development and the "Healthy China 2030" plan outline regard maternal and child safety and child health as important contents. Ensuring maternal and child safety is the ardent expectation of hundreds of millions of families for a better life in a moderately prosperous society. "Born because of love, born for love", caring starts from the beginning of life. The Reproductive Medicine Center of the Third Hospital of Beijing Medical University has been making unremitting efforts; fertility is healthy and thrives. We insist on being a good disseminator of health knowledge and continuously improve fertility health. The level of health care services, with the diagnosis and treatment of infertility as the core and the goal of obtaining healthy descendants, solves problems and brings happiness to millions of families. May every life be treated gently, and every beloved person be a happy baby. May every family's dreams come true!

Hospital Address: No. 49 Huayuan North Road, Haidian District, Beijing

If you want to learn more about the multinational assisted reproduction program, you can also contact the professional customer service of the Reproductive Medicine Center of Peking University Third Hospital for free consultation. Customer service telephone: 18101365219